Hutchison China Meditech Limited

Director's Share Dealing

HONG KONG, CHINA--(Marketwired - Oct 12, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

Director's Share Dealing

London: Wednesday, October 12, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, has sold 15,000 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at a price of GBP17.90 per share on October 7, 2016.

Following the above transaction, the holding of Mr Howell is 138,600 Ordinary Shares, representing approximately 0.23% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1		Details of the person discharging managerial responsibilities/person closely associated
a)		Name		Mr Michael Howell
2		Reason for the notification
a)		Position/status		Independent Non-executive Director of Chi-Med
b)		Initial notification/Amendment		Initial notification
3		Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)		Name		Hutchison China MediTech Limited
b)		LEI		N/A
4		Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)		Description of the financial instrument, type of instrument Identification code		Ordinary Shares of US$1.00 each DI ISIN: KYG4672N1016 ADS ISIN: US44842L1035
b)		Nature of the transaction		Sale of 15,000 Ordinary Shares on October 7, 2016 at a price of GBP17.90
c)		Price(s) and volume(s)
				Price(s)		Volume(s)
				GBP17.90		15,000
d)		Aggregated information		N/A
		- Aggregated volume
		- Price
e)		Date of the transaction		2016-10-07
f)		Place of the transaction		London Stock Exchange (XLON)

NOTES TO EDITORS

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries
Christian Hogg, CEO		[phone]
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson		[phone] (Mobile)		[e-mail]
U.S. Based Media Enquiries
Brad Miles, BMC Communications		[phone] (Mobile)		[e-mail]
Susan Duffy, BMC Communications		[phone] (Mobile)		[e-mail]
Investor Relations
Matt Beck, The Trout Group		[phone] (Mobile)		[e-mail]
David Dible, Citigate Dewe Rogerson		[phone] (Mobile)		[e-mail]
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts		[phone]

Contact:
RNS
Customer Services
0044-207797-4400
[e-mail]
http://www.rns.com